Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
3.775
+0.105 (2.86%)
At close: Oct 5, 2026, 4:00 PM EDT
3.770
-0.005 (-0.13%)
After-hours: Oct 5, 2026, 4:10 PM EDT
Prelude Therapeutics Revenue
Prelude Therapeutics had revenue of $5.70M in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to $22.42M, up 220.34% year-over-year. In the year 2025, Prelude Therapeutics had annual revenue of $12.14M with 73.43% growth.
Revenue (ttm)
$22.42M
Revenue Growth
+220.34%
P/S Ratio
17.32
Revenue / Employee
$283,848
Employees
79
Market Cap
388.81M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 12.14M | 5.14M | 73.43% |
| Dec 31, 2024 | 7.00M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Agenus | 132.69M |
| Enanta Pharmaceuticals | 65.26M |
| vTv Therapeutics | 36.84M |
| C4 Therapeutics | 35.04M |
| Arcturus Therapeutics Holdings | 29.37M |
| Opus Genetics | 9.86M |
| Inhibikase Therapeutics | 1.00 |
PRLD News
- 18 days ago - Prelude Therapeutics initiated with an Overweight at JPMorgan - TheFly
- 19 days ago - Prelude Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 24 days ago - Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewsWire
- 25 days ago - Prelude Therapeutics receives FDA clearance for PRT13722 IND application - TheFly
- 25 days ago - Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader - GlobeNewsWire
- 7 weeks ago - Prelude Therapeutics Earnings release: Q2 2026 - Filings
- 7 weeks ago - Prelude Therapeutics Quarterly report: Q2 2026 - Filings
- 7 weeks ago - Prelude Therapeutics reports Q2 EPS (14c), consensus (19c) - TheFly